Antonia Kalushkova

Uppsala, C, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Combinatorial DNMTs and EZH2 inhibition reprograms the H3K27me3 and DNAme-mediated onco-epigenome to suppress multiple myeloma proliferation.

Combinatorial DNMTs and EZH2 inhibition reprograms the H3K27me3 and DNAme-mediated onco-epigenome to suppress multiple myeloma proliferation.

Journal: Scientific reports

Published: March 24, 2025

The complex nature of lncRNA-mediated chromatin dynamics in multiple myeloma.

The complex nature of lncRNA-mediated chromatin dynamics in multiple myeloma.

Journal: Frontiers in oncology

Published: September 28, 2023

Dual targeting of G9a and DNMTs induces antitumor effects in multiple myeloma.

Dual targeting of G9a and DNMTs induces antitumor effects in multiple myeloma.

Journal: Blood advances

Published: May 09, 2023

PVT1 interacts with polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma.

PVT1 interacts with polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma.

Journal: Haematologica

Published: March 01, 2023

Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma.

Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma.

Journal: Cancer research

Published: June 28, 2022

One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies.

One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies.

Journal: Epigenomes

Published: July 14, 2021

A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma.

A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma.

Journal: Cell death & disease

Published: July 09, 2020

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains.

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains.

Journal: Oncotarget

Published: February 14, 2017

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.

Journal: Oncotarget

Published: October 09, 2016

A Role for the Chromatin-Remodeling Factor BAZ1A in Neurodevelopment.

A Role for the Chromatin-Remodeling Factor BAZ1A in Neurodevelopment.

Journal: Human mutation

Published: December 30, 2015

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.

Journal: Oncotarget

Published: June 03, 2015

Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia.

Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia.

Journal: The Journal of experimental medicine

Published: October 23, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026